Tenaya Therapeutics (TNYA) Competitors $1.13 +0.01 (+0.89%) Closing price 04:00 PM EasternExtended Trading$1.12 0.00 (-0.44%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TNYA vs. PRME, ESPR, RGNX, TRML, MBX, ACB, TERN, FHTX, TSHA, and CYRXShould you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include Prime Medicine (PRME), Esperion Therapeutics (ESPR), REGENXBIO (RGNX), Tourmaline Bio (TRML), MBX Biosciences (MBX), Aurora Cannabis (ACB), Terns Pharmaceuticals (TERN), Foghorn Therapeutics (FHTX), Taysha Gene Therapies (TSHA), and Cryoport (CYRX). These companies are all part of the "pharmaceutical products" industry. Tenaya Therapeutics vs. Prime Medicine Esperion Therapeutics REGENXBIO Tourmaline Bio MBX Biosciences Aurora Cannabis Terns Pharmaceuticals Foghorn Therapeutics Taysha Gene Therapies Cryoport Prime Medicine (NYSE:PRME) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking. Which has more risk & volatility, PRME or TNYA? Prime Medicine has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.84, suggesting that its stock price is 184% more volatile than the S&P 500. Does the MarketBeat Community prefer PRME or TNYA? Tenaya Therapeutics received 15 more outperform votes than Prime Medicine when rated by MarketBeat users. Likewise, 82.22% of users gave Tenaya Therapeutics an outperform vote while only 61.11% of users gave Prime Medicine an outperform vote. CompanyUnderperformOutperformPrime MedicineOutperform Votes2261.11% Underperform Votes1438.89% Tenaya TherapeuticsOutperform Votes3782.22% Underperform Votes817.78% Which has higher earnings & valuation, PRME or TNYA? Prime Medicine is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime MedicineN/AN/A-$198.13M-$2.05-1.56Tenaya TherapeuticsN/AN/A-$124.08M-$1.44-0.77 Do institutionals & insiders have more ownership in PRME or TNYA? 70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 23.5% of Prime Medicine shares are held by company insiders. Comparatively, 32.8% of Tenaya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is PRME or TNYA more profitable? Tenaya Therapeutics' return on equity of -86.17% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Prime MedicineN/A -107.87% -74.97% Tenaya Therapeutics N/A -86.17%-71.14% Do analysts rate PRME or TNYA? Prime Medicine currently has a consensus price target of $13.13, suggesting a potential upside of 310.80%. Tenaya Therapeutics has a consensus price target of $17.33, suggesting a potential upside of 1,454.56%. Given Tenaya Therapeutics' higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than Prime Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Tenaya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer PRME or TNYA? In the previous week, Prime Medicine's average media sentiment score of 1.90 beat Tenaya Therapeutics' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the media. Company Overall Sentiment Prime Medicine Very Positive Tenaya Therapeutics Neutral SummaryTenaya Therapeutics beats Prime Medicine on 11 of the 15 factors compared between the two stocks. Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNYA vs. The Competition Export to ExcelMetricTenaya TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$88.33M$3.10B$5.81B$9.13BDividend YieldN/A1.58%5.28%3.98%P/E Ratio-0.7732.0525.8419.10Price / SalesN/A335.97470.4779.19Price / CashN/A182.7545.1138.24Price / Book0.544.127.615.13Net Income-$124.08M-$71.72M$3.19B$245.96M7 Day Performance17.73%1.46%-0.26%-0.57%1 Month Performance-20.36%3.80%3.04%0.39%1 Year Performance-78.72%-10.01%18.98%15.42% Tenaya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNYATenaya Therapeutics2.9778 of 5 stars$1.13+0.9%$17.33+1,433.9%-82.3%$89.52MN/A-0.78110PRMEPrime Medicine3.2688 of 5 stars$2.84+9.2%$13.13+362.1%-61.1%$372.49MN/A-1.39234Positive NewsESPREsperion Therapeutics4.4822 of 5 stars$1.86-0.5%$6.75+262.9%-29.4%$366.49M$116.33M-2.91200Short Interest ↓Analyst RevisionGap DownRGNXREGENXBIO3.9754 of 5 stars$7.30-0.3%$33.45+358.3%-60.4%$361.64M$90.24M-1.45370TRMLTourmaline Bio1.8414 of 5 stars$13.83+5.7%$54.00+290.5%-70.5%$354.60MN/A-4.9044News CoverageMBXMBX Biosciences2.6678 of 5 stars$10.41+15.8%$37.25+257.8%N/A$347.90MN/A0.0036Insider TradeNews CoverageACBAurora Cannabis0.2711 of 5 stars$6.31-4.7%N/A+47.3%$346.17M$200.35M126.231,073TERNTerns Pharmaceuticals4.3777 of 5 stars$4.06-0.5%$18.30+350.7%-46.7%$344.86MN/A-3.4440FHTXFoghorn Therapeutics2.7798 of 5 stars$6.13-0.5%$13.17+114.8%-10.0%$340.89M$34.15M-3.19120Positive NewsTSHATaysha Gene Therapies2.6102 of 5 stars$1.63+0.6%$6.63+306.4%-14.1%$334.05M$15.45M2.59180News CoverageCYRXCryoport2.7018 of 5 stars$6.73+0.4%$12.29+82.6%-56.1%$332.66M$233.26M-1.991,170 Related Companies and Tools Related Companies Prime Medicine Competitors Esperion Therapeutics Competitors REGENXBIO Competitors Tourmaline Bio Competitors MBX Biosciences Competitors Aurora Cannabis Competitors Terns Pharmaceuticals Competitors Foghorn Therapeutics Competitors Taysha Gene Therapies Competitors Cryoport Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TNYA) was last updated on 2/20/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredFeb. 26 Could Send Nvidia’s “Silent Partners” SoaringNvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
